Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2− early breast cancer: insights from a large cohort in central south China

These findings challenge the traditional nodal-centric risk stratification model and highlight important disparities in the patient populations defined by trial eligibility criteria. The data suggest that nearly 60% of HR+ EBC patients may qualify for adjuvant ribociclib therapy under NATALEE criteria, indicating a broader therapeutic eligibility than previously recognized and emphasizing the need for a more inclusive, biology-driven approach to treatment selection in HR+ EBC.